Turnip Extract Restores Blood Sugar Control in Diabetic Mice, Study Finds

A humble root vegetable long relegated to stew pots and traditional medicine cabinets is now at the center of a striking new study on type 2 diabetes. Researchers report that a carefully purified fraction of turnip root, rich in plant flavonoids, substantially improved blood sugar control, insulin sensitivity, and liver health in diabetic mice. The work, published in the Journal of Agriculture and Food Research, traces the vegetable’s anti-diabetic power to specific molecular components, including the flavones chrysin and apigenin, and maps out the signaling pathways through which they appear to act. If the findings can be replicated and extended to humans, they could add scientific weight to the idea that ordinary cruciferous vegetables contain pharmacologically meaningful compounds capable of tackling one of the world’s fastest-growing chronic diseases.

The research team began with a deceptively simple question: which parts of the turnip actually matter for metabolism? Rather than testing a crude extract and stopping there, the investigators employed an activity-guided purification strategy. They ground ten kilograms of dried turnip root, extracted it with ethanol, and then partitioned the resulting material into fractions of increasing chemical refinement. Each fraction was tested in a laboratory model of insulin resistance: HepG2 liver cells bathed in high glucose and palmitic acid, a fatty acid that mimics the lipid overload seen in obesity and diabetes. The researchers measured how much glucose the cells could absorb, a direct readout of insulin sensitivity, and systematically eliminated fractions that showed no activity or toxicity.

The purification funnel narrowed dramatically. Of the two major fractions produced by liquid-liquid partitioning, the n-butanol fraction outperformed the water fraction at promoting glucose uptake. Silica gel chromatography then split this fraction into five subfractions, one of which, designated T-2D, stood out clearly. A second round of reversed-phase chromatography generated four refined subfractions, and the winner was unambiguous: T-3B drove glucose uptake in insulin-resistant hepatocytes to the highest levels observed in the entire screening campaign, reaching nearly 6.9 millimolar under the assay conditions, all without harming cell viability. This stepwise approach, the authors argue, addresses a persistent weakness in natural product research, where crude mixtures and single isolated compounds are often studied in isolation, leaving the interactions among constituents undefined.

With the active fraction in hand, the team moved to animal testing. They used db/db mice, a classic spontaneous model of type 2 diabetes in which animals carry a mutation that renders them obese, insulin resistant, and dyslipidemic. Mice with fasting blood glucose above 11.1 millimolar were randomized into groups receiving either a low dose of T-3B, a high dose, the anti-diabetic drug rosiglitazone as a positive control, or vehicle alone. Treatment was delivered by daily oral gavage for eight consecutive weeks, with body weight, food intake, and fasting glucose tracked weekly throughout.

The metabolic improvements were substantial and, in several respects, dose-dependent. High-dose T-3B lowered fasting blood glucose significantly as early as the second week of treatment, while the low dose produced significant effects by week three. Oral glucose tolerance tests performed after eight weeks showed that treated mice cleared a glucose load far more efficiently than untreated diabetic controls, with the high-dose group’s area under the glucose curve rivaling that of the rosiglitazone group. Insulin tolerance tests confirmed that the treated animals had genuinely recovered sensitivity to the hormone, not merely altered some downstream glucose metric. Body weight and food intake also declined moderately in treated mice, beginning around the sixth week of intervention.

Blood chemistry added another layer of benefit. Circulating levels of glucagon-like peptide-1, or GLP-1, an incretin hormone secreted by intestinal cells that promotes insulin release and satiety, were markedly depressed in the untreated diabetic mice but substantially restored by T-3B treatment. The fraction also corrected the characteristic diabetic lipid profile: plasma triglycerides, total cholesterol, and low-density lipoprotein all fell at the high dose, while high-density lipoprotein rose at both doses tested. Because elevated triglycerides and LDL cholesterol contribute to atherosclerotic risk in diabetic patients, the authors note that this dual glucose-and-lipid effect is exactly the profile sought in next-generation metabolic therapies, and one that many existing drugs only partially achieve.

The liver emerged as the fraction’s primary target organ. Histological staining revealed that untreated db/db mice livers were riddled with fat droplets, with ballooned hepatocytes and disordered tissue architecture, hallmarks of non-alcoholic fatty liver disease. T-3B treatment visibly reversed this steatosis, and biochemical assays confirmed reduced hepatic triglyceride content. Intriguingly, hepatic glycogen, the storage form of glucose, increased significantly in treated mice, while skeletal muscle glycogen remained unchanged, sharpening the picture of a liver-specific mechanism. The researchers propose that this matters because hepatic insulin resistance is an early and central driver of type 2 diabetes: when the liver stops responding to insulin, it churns out glucose uncontrollably while simultaneously importing fatty acids that worsen fat accumulation, creating a self-reinforcing vicious cycle between lipid deposition and metabolic dysfunction.

Molecular and genomic analyses converged on two well-known signaling hubs. Western blotting showed that diabetic mouse livers had blunted phosphorylation of the insulin receptor beta, insulin receptor substrate 1, AKT, and AMPK alpha, the canonical cascade through which insulin instructs the liver to store glucose and cease glucose production. Eight weeks of T-3B treatment rescued these phosphorylation defects in a dose-dependent manner, and parallel experiments in insulin-resistant HepG2 cells reproduced the effect within twenty-four hours. RNA sequencing of liver tissue reinforced the story at the transcriptomic level: more than 1,600 genes changed expression after treatment, with downregulated genes enriched in inflammatory pathways such as NF-kappaB and TNF signaling, oxidative stress responses, and cellular senescence, while upregulated genes clustered in fatty acid oxidation, the PPAR pathway, glycogen biosynthesis, and AMPK signaling itself.

Chemical fingerprinting of T-3B by high-performance liquid chromatography coupled with mass spectrometry and nuclear magnetic resonance identified six monomeric constituents: trans-4-hydroxycinnamic acid, chrysin, ferulic acid, trans-ferulic acid, 4-hydroxy-3,5-dimethoxycinnamic acid, and apigenin. When each was tested individually in insulin-resistant liver cells at twenty micromolar, chrysin and apigenin proved the strongest promoters of glucose uptake, with chrysin the single most potent compound despite not being the most abundant. Combining chrysin and apigenin produced an enhanced effect beyond simple addition, which the authors attribute to their shared flavone backbone and complementary regulatory pathways. Chrysin alone also reduced triglyceride and cholesterol accumulation in fat-injured liver cells, lowered markers of cellular damage, boosted the antioxidant enzyme superoxide dismutase, and reduced malondialdehyde, a marker of oxidative injury.

The authors are careful to flag the limits of their work. The reduced food intake observed in treated mice could partly confound the metabolic benefits, and the team acknowledges that pair-fed control groups would be needed to fully disentangle direct drug effects from dietary restriction. The signaling findings, while consistent, remain correlative without inhibitor or gene-knockdown experiments, the transcriptomic results await validation by quantitative PCR, and the absolute quantities and purity of the individual monomers were not fully quantified. The mechanism behind the restored GLP-1 secretion, whether direct stimulation of intestinal cells, gut signaling, or microbiome remodeling, also remains speculative. Still, the study delivers something the field has lacked: a defined, purified turnip fraction with a mapped component-pathway-phenotype network connecting specific flavones to insulin and energy-sensing signaling in the liver. As diabetes prevalence in China now exceeds twelve percent, well above the global average, and drug side effects push patients toward dietary alternatives, the prospect that a common vegetable harbors multi-target metabolic activity is a finding worth watching closely.

Subject of Research: Bioactive turnip compounds as potential treatments for type 2 diabetes and hepatic insulin resistance

Article Title: Bioactive components from Turnip improve liver and systemic metabolic homeostasis in mice with T2DM

Article References: Ling, Z., Jin, L., Xu, W., Sun, M., Sun, J., Zhou, Z., Liu, Q., Wang, Y., Liu, J., Wu, J., Khattab, O. M., Fu, H., Shou, Q., & Han, J. (2026). Bioactive components from Turnip improve liver and systemic metabolic homeostasis in mice with T2DM. Journal of Agriculture and Food Research, 31, Article 103344. https://doi.org/10.1016/j.jafr.2026.103344

Image Credits: AI Generated

DOI: Not provided

Keywords: turnip, type 2 diabetes, chrysin, apigenin, insulin resistance, liver metabolism, db/db mice, AMPK, PI3K-AKT, flavonoids, GLP-1, fatty liver disease